Bach & Godofsky Infectious Diseases

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy

John D. Baxter, Douglas L. Mayers, Deborah Wentworth et al. · AIDS · 2000 · 502 citations

Pharmacy, Pharmacotherapy, Molecular Virology +16

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients

Ira M. Jacobson, Robert S. Brown, Bradley Freilich et al. · Hepatology · 2007 · 306 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Antiretroviral Activity of the Anti‐CD4 Monoclonal Antibody TNX‐355 in Patients Infected with HIV Type 1

Daniel R. Kuritzkes, Jeffrey M. Jacobson, William G. Powderly et al. · The Journal of Infectious Diseases · 2004 · 193 citations

Pharmacy, Infectious Diseases, Pharmacology +17

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

Jeffrey M. Jacobson, Daniel R. Kuritzkes, Eliot Godofsky et al. · Antimicrobial Agents and Chemotherapy · 2008 · 160 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin†

Paul J. Pockros, David R. Nelson, Eliot Godofsky et al. · Hepatology · 2008 · 101 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17